JP2014525402A - 非経口投与のための濃縮されたフェルバメート製剤 - Google Patents

非経口投与のための濃縮されたフェルバメート製剤 Download PDF

Info

Publication number
JP2014525402A
JP2014525402A JP2014525143A JP2014525143A JP2014525402A JP 2014525402 A JP2014525402 A JP 2014525402A JP 2014525143 A JP2014525143 A JP 2014525143A JP 2014525143 A JP2014525143 A JP 2014525143A JP 2014525402 A JP2014525402 A JP 2014525402A
Authority
JP
Japan
Prior art keywords
solvent
neuroprotective agent
microparticles
solution
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014525143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525402A5 (enExample
Inventor
サシャ エイチ． バクル，
ブライアン イー． ローリクト，
エディス マシオウィッツ，
ソロモン エス． スタイナー，
Original Assignee
ペロスフィア インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペロスフィア インコーポレイテッド filed Critical ペロスフィア インコーポレイテッド
Publication of JP2014525402A publication Critical patent/JP2014525402A/ja
Publication of JP2014525402A5 publication Critical patent/JP2014525402A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014525143A 2011-08-12 2012-08-09 非経口投与のための濃縮されたフェルバメート製剤 Withdrawn JP2014525402A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522811P 2011-08-12 2011-08-12
US61/522,811 2011-08-12
PCT/US2012/050148 WO2013025442A2 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017079599A Division JP2017122127A (ja) 2011-08-12 2017-04-13 非経口投与のための濃縮されたフェルバメート製剤

Publications (2)

Publication Number Publication Date
JP2014525402A true JP2014525402A (ja) 2014-09-29
JP2014525402A5 JP2014525402A5 (enExample) 2015-09-24

Family

ID=47715640

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014525143A Withdrawn JP2014525402A (ja) 2011-08-12 2012-08-09 非経口投与のための濃縮されたフェルバメート製剤
JP2017079599A Ceased JP2017122127A (ja) 2011-08-12 2017-04-13 非経口投与のための濃縮されたフェルバメート製剤
JP2019022430A Pending JP2019085416A (ja) 2011-08-12 2019-02-12 非経口投与のための濃縮されたフェルバメート製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017079599A Ceased JP2017122127A (ja) 2011-08-12 2017-04-13 非経口投与のための濃縮されたフェルバメート製剤
JP2019022430A Pending JP2019085416A (ja) 2011-08-12 2019-02-12 非経口投与のための濃縮されたフェルバメート製剤

Country Status (7)

Country Link
US (2) US20140178479A1 (enExample)
EP (1) EP2741751A4 (enExample)
JP (3) JP2014525402A (enExample)
AU (1) AU2012295390B2 (enExample)
CA (1) CA2844907A1 (enExample)
HK (1) HK1198942A1 (enExample)
WO (1) WO2013025442A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041426T2 (hu) 2009-11-02 2019-05-28 Univ Washington Terápiás nukleáz-készítmények és eljárások
CA2834626A1 (en) 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015100252A1 (en) * 2013-12-23 2015-07-02 Perosphere, Inc. Deuterated felbamate, compositions containing the same, and methods of use thereof
GB201604359D0 (en) * 2016-03-15 2016-04-27 Univ Newcastle Treatment of tissue disorders
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536409A (ja) * 1999-02-09 2002-10-29 ユニバーシティ オブ バージニア パテント ファウンデーション フェルバメートから誘導される化合物
JP2006528985A (ja) * 2003-05-19 2006-12-28 バクスター・インターナショナル・インコーポレイテッド １つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子
JP2009523802A (ja) * 2006-01-17 2009-06-25 リージェンツ オブ ザ ユニバーシティー オブ コロラド Ｃｎｓ状態のための治療剤の安定製剤の中枢投与

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1904257A (en) * 1926-10-29 1933-04-18 Firm Of Chemical Works Formerl Supersaturated calcium gluconate solution
US3017323A (en) * 1957-07-02 1962-01-16 Pfizer & Co C Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics
US5308621A (en) * 1991-02-18 1994-05-03 Commonwealth Scientific And Industrial Research Organisation Ascorbic acid composition and transdermal administration method
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
AU5967101A (en) 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
EP1594515A4 (en) * 2003-02-03 2009-05-27 Supernus Pharmaceuticals Inc FORMULATION AND ADMINISTRATION OF A MEDICINAL PRODUCT USING METHYLATED CRYSTALLINE CYCLODEXTRINS
WO2004105699A2 (en) 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
WO2009017825A2 (en) 2007-08-02 2009-02-05 The General Hospital Corporation Novel lipoxygenase inhibitors as neuroprotective agents
CA2720254A1 (en) * 2008-04-01 2009-12-17 Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the intracerebroventricular administration of felbamate
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
AU2012250050B2 (en) * 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536409A (ja) * 1999-02-09 2002-10-29 ユニバーシティ オブ バージニア パテント ファウンデーション フェルバメートから誘導される化合物
JP2006528985A (ja) * 2003-05-19 2006-12-28 バクスター・インターナショナル・インコーポレイテッド １つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子
JP2009523802A (ja) * 2006-01-17 2009-06-25 リージェンツ オブ ザ ユニバーシティー オブ コロラド Ｃｎｓ状態のための治療剤の安定製剤の中枢投与

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMACEUTICAL RESEARCH, vol. 21, no. 2, JPN6016018510, 2004, pages 201 - 230, ISSN: 0003320657 *

Also Published As

Publication number Publication date
AU2012295390B2 (en) 2015-12-24
AU2012295390A1 (en) 2014-03-13
WO2013025442A3 (en) 2013-04-25
US20140178479A1 (en) 2014-06-26
JP2019085416A (ja) 2019-06-06
EP2741751A2 (en) 2014-06-18
CA2844907A1 (en) 2013-02-21
US20170157083A1 (en) 2017-06-08
WO2013025442A2 (en) 2013-02-21
EP2741751A4 (en) 2015-03-25
HK1198942A1 (en) 2015-06-19
JP2017122127A (ja) 2017-07-13

Similar Documents

Publication Publication Date Title
JP2017122127A (ja) 非経口投与のための濃縮されたフェルバメート製剤
US10821098B2 (en) Treatment using dantrolene
US20130183371A1 (en) Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
JP3218038B2 (ja) 尿酸排泄促進剤およびｅａａ拮抗剤の組合せのための医薬組成物
US20100062066A1 (en) Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
JP2002539257A (ja) 薬剤の脳内生物学的利用率の増加
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
EP1603513B1 (en) Dantrolene compositions
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
JP2023510173A (ja) 中枢神経系障害の処置及び防止のための化合物
CN119384294A (zh) 用于治疗蠕形螨相关病症的抗胆碱能剂和毒蕈碱激动剂
JP2024090829A (ja) 滅菌容器に収容されるエピナスチン含有水性医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180405